development digital therapeutics investing 
TechCrunch
SEPTEMBER 9, 2021
Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. million to develop digital therapeutics for neurodegenerative diseases. Venture investing in elder tech.
TechCrunch
DECEMBER 20, 2021
GHI Fund President Bill Taranto has spent more than two decades in the healthcare industry and has 15 years of experience in healthcare investing. In addition to his venture investing knowledge, Bill has decades of management operations experience. 4 strategies for building a digital health unicorn. Share on Twitter.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch
APRIL 6, 2022
As a venture firm that invests in psychedelics, we receive hundreds of pitches every month from founders developing psychedelic therapeutics. Our fund has invested more than $15 million in companies developing psychedelic therapeutics. So how do we pick which companies to invest in? Share on Twitter.
TechCrunch
NOVEMBER 3, 2021
BrainCheck , a Houston- and Austin-based company developing cognitive healthcare software to aid physicians in detecting and managing this type of care, raised $10 million in Series B funding to expand its R&D and go-to-market capabilities as it works on new digital therapeutics for Alzheimer’s and related dementias.
HPA
MARCH 15, 2022
We’re excited to share that metaMe Health , a prescription digital therapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
HPA
MARCH 15, 2022
We’re excited to share that metaMe Health , a prescription digital therapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
AsiaTechDaily
APRIL 30, 2022
Register Biofourmis , a Sigapore-founded digital therapeutics firm , announced that it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. With this investment, Biofourmis plans to scale up its virtual care offerings, according to the announcement.
Expert insights. Personalized for you.
93 
Let's personalize your content